Floatz logo

cd4+ t cells

Leukemia, Myeloid, Chronic

Masonic Cancer Center, University of MinnesotaCell therapyN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

86 Active assets in the Leukemia, Myeloid, Chronic cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
City of Hope Medical Center
Phase 3BBB
Nilotinib
Novartis Pharmaceuticals
Phase 4BBB
Fludarabine
Fred Hutchinson Cancer Center
Phase 3BBB
Therapeutic Allogeneic Lymphocytes
University of Chicago
Phase 2BBB
Romidepsin
Center for International Blood and Marrow Transplant Research
Phase 2BBB

View all 50 →

Same molecule, other indications

cd4+ t cells is also rated in:

SarcomaDormant
C
Indicative ·
39 / 100
View asset →
MelanomaDormant
C
Indicative ·
37 / 100
View asset →
myelodysplastic syndromeDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →